Julphar manufactures a variety of products, mainly under license including anti-biotics for the UK's SmithKline Beecham. Julphar announced plans in 1999 to build a second factoring unit. Its paid up capital stands at 300 million dirhams divided into 300 million shares of one dirham each.

Individuals	N/A
Institutions	N/A
Floating	N/A
Government	20%

Chairman	Saud Sakr Al Qassimi
Vice Chairman	Yousuf Abdul Razzak

	2005	2004	2003
Total Assets	1,025,886	822,814	736,707
Shareholder's Equity	753,528	634,664	501,617
NIAT	116,876	67,074	56,479
Dividends	N/A	N/A	36,000

	2005	2004	2003
Assets Growth	24.68%	11.69%	12.22%
Earning Growth	74.25%	18.76%	31.32%
ROaA	12.64%	8.60%	8.11%
ROaE	16.84%	11.81%	11.51%
No. Of Shares	300,000,000	300,000,000	300,000,000
EPS	0.39	0.22	0.19
EPS Growth	74.25%	18.76%	31.32%
Payout Ratio	N/A	N/A	63.741

	Trailing
PE	10.09
PB
DVPS	N/A
Div Yield	N/A
EV	1,488,000.00
EV/Equity	1.98

The information is this section is provided by SHUAA Capital PSC. The information contained in this section is not intended to be an offer, a recommendation, or a solicitation to buy or sell securities or investment products.

The information and opinions contained in this section have been compiled from, or arrived at in good faith, from sources believed to be reliable but no guarantee or warranty is made by SHUAA Capital or AME Info as to the accuracy or completeness of the information contained herein.

All opinions expressed herein are subject to change without notice.

Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of AME Info FZ LLC.

© SHUAA Capital PSC. All rights reserved.